<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03353298</url>
  </required_header>
  <id_info>
    <org_study_id>2017/397 C</org_study_id>
    <secondary_id>2017-000666-30</secondary_id>
    <nct_id>NCT03353298</nct_id>
  </id_info>
  <brief_title>Lowering Uric Acid in Live Kidney Donors</brief_title>
  <acronym>AL-DON</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, 9-month, Parallel Group Study of Allopurinol to Reduce Left Ventricular Mass in Living Kidney Donors (AL-DON)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>South-Eastern Norway Regional Health Authority</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently there was described an increase in left ventricular mass after kidney donation. It
      is uncertain whether this is reversible or not. Allopurinol lowers uric acid in the blood and
      is normally indicated for gout, but studies have showed that it also can reduce the thickness
      of the left ventricle of the heart in people with heart- and kidney disease.

      The investigators wish to give allopurinol or placebo to kidney donors based on randomization
      and investigate if this has the same effect on kidney donors. The investigators are assessing
      this by performing a cardiac MRI at baseline and after 9 months of treatment. In addition the
      investigators wish to see if allopurinol can have beneficial effects on blood pressure and
      insulin sensitivity as well.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in left ventricular mass</measure>
    <time_frame>Nine months</time_frame>
    <description>Measured change in left ventricular mass using Cardiac MRI, comparing from baseline to 9 months of treatment With allopurinol compared to placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>Nine months</time_frame>
    <description>Change from baseline to 9 months in the allopurinol group compared to placebo in systolic and diastolic ambulatory blood pressure, systolic and diastolic Office blood pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated insulin sensitivity, metabolic clearance rate of glucose</measure>
    <time_frame>Nine months</time_frame>
    <description>Change from baseline to 9 months in the allopurinol group compared to placebo in insulin sensitivity using an orgal glucose tolerance test to measure estimated metabolic clearance rate of glucose, insulin sensitivity, firth-phase insulin release and second-phase insulin release.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of antihypertensive medications</measure>
    <time_frame>Nine months</time_frame>
    <description>Change from baseline to 9 months in the allopurinol group compared to placebo in number of antihypertensive medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Doses of antihypertensive medications</measure>
    <time_frame>Nine months</time_frame>
    <description>Change from baseline to 9 months in the allopurinol group compared to placebo in doses of antihypertensive medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urinary albumin excretion</measure>
    <time_frame>Nine months</time_frame>
    <description>Change from baseline to 9 months in the allopurinol group compared to placebo in urinary albumin excretion by measuring urinary albumin/creatinine ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in estimated GFR</measure>
    <time_frame>Nine months</time_frame>
    <description>Change from baseline to 9 months in the allopurinol group compared to placebo in estimated GFR</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Renal Transplant Donor of Left Kidney</condition>
  <condition>Renal Transplant Donor of Right Kidney</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Allopurinol 300 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Oral tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol 300 mg</intervention_name>
    <description>Allopurinol oral tablets 300 mg given to participants once daily for 9 months</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>placebo oral tablets given to participants once daily for 9 months</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Kidney donor ≥ 6 months after donor nephrectomy

          2. Donor nephrectomy undertaken in Norway

          3. Male or female subject ≥ 18 years old

          4. eGFR &gt;30 ml/min/1.73 m2

          5. Signed informed consent and expected cooperation of the patients for the treatment and
             follow up must be obtained and documented according to ICH GCP, and national/local
             regulations.

        Exclusion Criteria:

          1. Adverse reactions to allopurinol or other xanthine oxidase inhibitors

          2. Use of uric acid lowering therapy within 3 months

          3. History of gout, xanthinuria or other indications for uric acid lowering therapy such
             as cancer chemotherapy

          4. History of renal calculi

          5. History of coronary heart disease

          6. Heart failure with left ventricular ejection fraction &lt;45%

          7. History of significant (i.e. non-physiological) cardiac valvular stenosis or
             insufficiency

          8. History of clinically significant hepatic disease including hepatitis B or C and/or
             ALAT (SGPT) above the upper reference limit at screening.

          9. History of HIV or AIDS

         10. Severe systemic infections, current or within the last 6 months

         11. History of malignancy other than localized basal cell carcinoma of the skin, treated
             or untreated, within the past 5 years.

         12. Other life-threatening diseases

         13. Haemoglobin concentration &lt; 11 g/dL(males), &lt;10 g/dL (females); white blood cell (WBC)
             count &lt; 3.5 * 10^9/L; platelet count &lt;50 *10^9/L at screening

         14. Use of the following medications at or within 14 days before the screening visit:
             azathioprine, mercaptopurine, vidarabin, chlorpropamide, warfarin, tamoxifen,
             theophylline, amoxicillin/ampicillin, cyclophosphamide, doksorubicin, bleomycin,
             prokarbazin, cyclosporine, didanosine.

         15. Contraindications to MRI, including: Magnetic intracranial clips. Metal fragments in
             orbita. Cochlea (ear) implant. Neurostimulator. Pacemaker/ICD or remaining pacemaker
             electrodes. Harrington rods in thorax. Claustrophobia. Unable to lie supine.

         16. Pregnant or nursing (lactating) women

         17. Fertile women, unless they are using effective contraception during dosing of study
             treatment

         18. Any reason why, in the opinion of the investigator, the patient should not
             participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dag Olav Dahle, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nina EB Langberg, MD</last_name>
    <phone>+47 97100792</phone>
    <email>nlangb@ous-hf.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dag Olav Dahle, MD, PhD</last_name>
    <email>dagdah@ous-hf.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NE Langberg</last_name>
      <email>nlangb@ous-hf.no</email>
    </contact>
    <contact_backup>
      <last_name>DO Dahle</last_name>
      <email>dagdah@ous-hf.no</email>
    </contact_backup>
    <investigator>
      <last_name>DO Dahle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Moody WE, Ferro CJ, Edwards NC, Chue CD, Lin EL, Taylor RJ, Cockwell P, Steeds RP, Townend JN; CRIB-Donor Study Investigators. Cardiovascular Effects of Unilateral Nephrectomy in Living Kidney Donors. Hypertension. 2016 Feb;67(2):368-77. doi: 10.1161/HYPERTENSIONAHA.115.06608.</citation>
    <PMID>26754643</PMID>
  </reference>
  <reference>
    <citation>Kao MP, Ang DS, Gandy SJ, Nadir MA, Houston JG, Lang CC, Struthers AD. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol. 2011 Jul;22(7):1382-9. doi: 10.1681/ASN.2010111185. Epub 2011 Jun 30.</citation>
    <PMID>21719783</PMID>
  </reference>
  <reference>
    <citation>Altmann U, Böger CA, Farkas S, Mack M, Luchner A, Hamer OW, Zeman F, Debl K, Fellner C, Jungbauer C, Banas B, Buchner S. Effects of Reduced Kidney Function Because of Living Kidney Donation on Left Ventricular Mass. Hypertension. 2017 Feb;69(2):297-303. doi: 10.1161/HYPERTENSIONAHA.116.08175. Epub 2017 Jan 3.</citation>
    <PMID>28049698</PMID>
  </reference>
  <reference>
    <citation>Rekhraj S, Gandy SJ, Szwejkowski BR, Nadir MA, Noman A, Houston JG, Lang CC, George J, Struthers AD. High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. J Am Coll Cardiol. 2013 Mar 5;61(9):926-32. doi: 10.1016/j.jacc.2012.09.066.</citation>
    <PMID>23449426</PMID>
  </reference>
  <reference>
    <citation>Szwejkowski BR, Gandy SJ, Rekhraj S, Houston JG, Lang CC, Morris AD, George J, Struthers AD. Allopurinol reduces left ventricular mass in patients with type 2 diabetes and left ventricular hypertrophy. J Am Coll Cardiol. 2013 Dec 17;62(24):2284-93. doi: 10.1016/j.jacc.2013.07.074. Epub 2013 Aug 28.</citation>
    <PMID>23994420</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2017</study_first_submitted>
  <study_first_submitted_qc>November 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2017</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Dag Olav Dahle</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Uric acid</keyword>
  <keyword>Left ventricular mass</keyword>
  <keyword>Nephrectomy</keyword>
  <keyword>Allopurinol</keyword>
  <keyword>Magnetic resonance imaging</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Uric Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

